S107
CAS No. 927871-76-9
S107( —— )
Catalog No. M17667 CAS No. 927871-76-9
S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 61 | In Stock |
|
| 2MG | 30 | In Stock |
|
| 5MG | 55 | In Stock |
|
| 10MG | 84 | In Stock |
|
| 25MG | 152 | In Stock |
|
| 50MG | 249 | In Stock |
|
| 100MG | 355 | In Stock |
|
| 200MG | 505 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameS107
-
NoteResearch use only, not for human use.
-
Brief DescriptionS107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.
-
DescriptionS107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number927871-76-9
-
Formula Weight209.31
-
Molecular FormulaC11H15NOS
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 38 mg/mL; 181.55 mM
-
SMILESCN1CCSc2c(C1)cc(cc2)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lehnart SE, et al. J Clin Invest. 2008 Jun;118(6):2230-45.
molnova catalog
related products
-
Charantin
Charantin is a steroidal saponin isolated from Momordica charantia. It increases the release of insulin and slowing down gluconeogenesis. Charantin can inhibit GSK-3.
-
HCV Core Protein (19...
PQDVKFP is a synthetic peptide, recognizing antigenic domains within the hepatitis C virus (HCV) core protein.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
Cart
sales@molnova.com